Design and discovery of novel, potent pyrazinone-based thrombin inhibitors with a solubilizing amino P1-P2-linker

Letters in Drug Design and Discovery

Volumn 3, Issue 5, 2006, Pages 289-292

  Bulat, S ^a   Bosio, S ^a   Papadopoulos, M A ^a   Cerezo Galvez S ^a   Grabowski, E ^a   Rosenbaum, C ^a   Matassa, V G ^a   Ott, I ^a   Metz, G ^a   Schamberger, J ^a   Sekul, R ^a   Feurer, A ^a  

^a Santhera Pharmaceuticals   (Switzerland)

Author keywords

Binding mode; Pyrazinone; Selectivity; Thrombin; X ray

Indexed keywords

1 (6 AMINO 2 METHYL 3 PYRIDINYLMETHYLAMINOCARBONYLMETHYL) 3 PHENETHYLAMINO 6 METHYL 2 PYRAZINONE; ACETAMIDE; AMINO ACID; DABIGATRAN; GLUTAMIC ACID; PYRAZINONE DERIVATIVE; SOLUBILIZER; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN;

ARTICLE; BINDING AFFINITY; CHEMICAL ANALYSIS; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG EFFECT; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; PRIORITY JOURNAL; PROTEIN INTERACTION; RESIDUE ANALYSIS; SURFACE PLASMON RESONANCE; X RAY; X RAY CRYSTALLOGRAPHY;

EID: 33745620719     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018006777574203     Document Type: Article

References (20)

1. Goldsack, N.R.; Chambers, R.C.; Dabbag, K.; Laurent, J. Int. J. Biochem. Cell Biol. 1998, 30, 641-646.
2. Fuster, V.; Verstraete, M. Thrombosis in Cardio-vascular Disorders, Elsevier Science Health Science, Philadelphia, 1992.
3. (a) Vacca, J.P.; Curr. Opin. Chem. Bio. 2000, 4, 394-400;
4. (b) Coburn, C.A.; Exp. Opin. Ther. Patents 2001, 11, 721-738.
5. Crowther, M.A.; Weitz, J.I. Exp. Opin. Investig. Drugs 2004, 13, 403-413.
6. Sanderson, P.E.J.; Lyle, T.A.; Cutrona, K.J.; Dyer, D.L.; Dorsey, B.D.; McDonough, C.M.; Naylor-Olsen, A.M.; Chen, I.-W.; Chen., Z.; Cook, C.M.; Gardell, S.J.; Hare, T.R.; Krueger, J.A.; Lewis, S.D.; Lin, J.H.; Lucas, B.J.; Lyle, E.A.; Lynch, J.J.; Stranieri, M.T.; Vastag, K.; Yan, Y.; Shafer, J.A.; Vacca, J.P. J. Med. Chem. 1998, 41, 4466-4474.
7. Hauel, N.H.; Nar, H.; Priepke, H.; Ries, U.; Strassen, J.-M.; Wienen, W. J. Med. Chem. 2002, 45, 1757-1766.
8. For recent reviews, see: Ries, U.; Wienen, W. Drugs Future 2003, 28, 355-370;
9. Pfau, R. Curr. Opin. Drug Disc. Dev. 2003, 6, 437-450.
10. Neumann, T.; Junker, H.-D.; Keil, O.; Burkert, K.; Ottleben, H.; Gamer, J.; Sekul, R.; Deppe, H.; Feurer, A.; Tomandl, D.; Metz, G. Lett. Drug Des. Discovery 2005, 2 (8), 590-594.
11. Lumma, W.C.; Witherup, K.M.; Tucker, T.J.; Brady, S.F.; Sisko, J.T.; Naylor-Olsen, A.D.; Lewis, S.D.; Lucas, B.J.; Vacca, J.P. J. Med. Chem. 1998, 41, 1011-1013.
12. To find amine replacements in 5, commercial databases were searched for small primary amines using a flexible 3D pharmacophore search. The query based on the extrapolated binding mode of 5 comprises the following features: 4 (5) spheres fixing the location of the primary amine and the center of a phenyl ring (or alternatively an aromatic 5/6 condensed bicycle of ANY atoms) as well as a spatial plane through the ring. The resulting hits were attached to the diphenylalanine proline scaffold. 5-Chlorobenzothiophene was selected based on minimization of these structures in the active site of thrombin. In the course of our work, similar findings for FXa inhibitors were reported: Coi-Sledeski, Y.M.; Kearney, R.; Poli, G.; Pauls, H.; Gardner, C.; Gong, Y.; Becker, M.; Davis, R.; Spada, A.; Liang, G.; Chu, V.; Brown, K.; Collussi, D.; Leadley, Jr., R.; Rebello, S.; Moxey, P.; Morgan, S.; Bentley, R.; Kasiewski, C.; Maignan, S.; Guilloteau, J.-P.; Mikol, V. J. Med. Chem. 2003, 46, 681-684;
13. Maignan, S.; Guilloteau, J.-P.; Choi-Sledeski, Y.M.; Becker, M.R.; Ewing, W.R.; Pauls, H.W.; Spada, A.P. ; Mikol V. J. Med. Chem. 2003, 46, 685-689;
14. Roehrig, S.; Straub, A.; Pohlmann, J.; Lampe, T.; Pernerstorfer, J.; Schlemmer, K.-H.; Reinemer, P.; Perzborn, E. J. Med. Chem. 2005, 48, 5900-5908.
15. Sanderson, P.E.J.; Dyer, D.L; Naylor-Olsen, A.M.; Vacca, J.P.; Gardell, S.J.; Lewis, S.D.; Lucas, Jr., B.J.; Lyle, E.A.; Lynch, Jr., J.J.; Mulichak A.M. Bioorg. Med. Chem. Lett. 1997, 7, 1497-1500.
16. Mack, H.; Pfeiffer, T.; Hornberger, W.; Boehm, H.-J.; Hoeffken, H.W. J. Enzyme Inhib. 1995, 9, 73-86.
17. Christopher S.; Burgey, C.S.; Robinson, K.A.; Lyle, T.A.; Nantermet, P.G.; Selnick, H.G.; Isaacs, R.C.A.; Lewis, S.D.; Lucas, B.J.; Krueger, J.A.; Singh, R.; Miller-Stein, C.; White, R.B.; Wong, B.; Lyle, E.A.; Stranieri, M.T.; Cook, J.J.; McMasters, D.R.; Pellicore, J.M.; Pal, S.; Wallace, A.A.; Clayton, F.C.; Bohn, D.; Welsh, D.C.; Lynch, Jr., J.J.; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S.J.; Shafer, J.A.; Vacca, J.P. Bioorg. Med. Chem Lett. 2003, 13, 1353-1357.
18. Burgey, S.C.; Robinson, K.A.; Lyle, T.A.; Sanderson, E.J.; Lewis, S.D.; Lucas, B.J.; Krueger, J.A.; Singh, R.; Miller-Stein, C.; White, R.B.; Wong, B.; Lyle, E.A.; Williams, P.D.; Coburn, C.A.; Dorsey, B.D.; Barrow, J.C.; Stranieri, M.T.; Holahan, M.A.; Sitko, G.R.; Cook, J.J.; McMasters, D.R.; McDonough, C.M.; Sanders, W.M.; Wallace, A.A.; Clayton, F.C.; Bohn, D.; Leonard, Y.M.; Detwiler, Jr., T.J.; Lynch, Jr., J.J.; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S.J.; Shafer, J.A.; Vacca, J.P. J. Med. Chem. 2003, 46, 461-473.
19. The resolution of the final structures were 3.2 Å (7), 1.8 Å for (8) and 2.8 Å (9). The structures are deposited in the PDB with the respective codes 2BVX (7), 2BXT (8) and 2BXU (9).
20. Young, M.B.; Barrow, J.C.; Glass, K.L.; Lundell, G.F.; Newton, C.L.; Pellicore, J.M.; Rittle, K.E.; Selnick, H.G.; Stauffer, K.J.; Vacca, J.P.; Williams, P.D.; Bohn, D.; Clayton, F.C.; Cook, J.J.; Krueger, J.A.; Kuo, L.C.; Lewis, S.D.; Lucas, B.J.; McMasters, D.R.; Miller-Stein, C.; Pietrak, B.L.; Wallace, A.A.; White, R.B.; Wong, B.; Yan, Y.; Nantermet, P. G. J. Med. Chem. 2004, 47, 2995-3008.